Introduction: Hypogonadotropic amenorrhea is one kind of primary amenorrhea which is caused by a decrease in GnRH secretion and results in infertility. As infertility is an important problem in 10-15% of couples, the present study was undertaken to determine the prevalence of the disease in infertile women and pregnancy rates in response to its treatment. Materials and Methods: This cross-sectional, analytical study included 35 subjects suffering from hypothalamic amenorrhea, pulled from 2150 patients who referred to the infertility center of Montaserieh Hospital in Mashad during 2000-2002. The gathered data included: the patients age, infertility duration, menstrual cycles, history of prior surgeries or illnesses, food regimens and drug history. A gynecologic exam, hormonal assays and sonographic evaluations were carried out. The patients underwent 3 cycles of ovulation induction procedures. A serum -hCG measurement and a vaginal sonography were used to confirm pregnancy. The data were analyzed by SPSS 11. For the descriptive analysis, t-test and logistic regression were used and the significance level was considered 5% (p<0.05). Results: The patients aged 20-35 and their infertility period varied from 1.5 to 14 years. Three of them were excluded from the study because of loss to follow up. The prevalence rate was 1-6%. In all of the patients, the serum FSH and LH levels were <5IU/ml. Serum prolactin levels were 21.7% 34.8 IU/ml and TSH 1.20.6 IU/ml. 14 patients out of 32, responded to treatment and became pregnant after three cycles of treatment (43.7%). Conclusion: The prevalence rate of infertility due to hypogonadotropic amenorrhea in this study was 0.016. Infertility due to hypogonadotropic amenorrhea is a disease that can respond to common ovulation induction treatment schedules quite well and despite the short period of treatment (3 cycles) in this study, 43.7% of the patients became pregnant. It is expected that by increasing the treatment period, better results will follow as it has in studies following 6 cycles of treatment with 83-90.1% success rates.